Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065177 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL23070802 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL414000 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL16987094 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL21388184 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL14297528 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL2799150 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL13531077 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL13952744 | 0.82 | CYP4F2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL22079331 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2DDB1CRBNHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215661-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-2854856-B1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2854856-B1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| US-9370516-B2 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders | PFIZER INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370516-B2 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders | PFIZER INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2547679-B1 | 2,3 DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER INC. (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER INC. (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER INC. (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2854856-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | Pfizer Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-104334193-A | Use of ghrelin receptor inverse agonists or antagonists for the treatment of sleep disorders | PFIZER | 2015-02-04 | — | — | CN | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2013182933-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | PFIZER INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | ALK, ROS1, ARSA | USP2 4592/4885SMN1; SMN2 3417/4885DDB1 3884/4885 |
| US-20150119381-A1 | USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS | GIPR, GHSR, HCRTR2 | USP2 2224/4885SMN1; SMN2 1427/4885DDB1 4803/4885 |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | GIPR, GLP1R, GHSR | USP2 3484/4885SMN1; SMN2 1617/4885DDB1 3718/4885 |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | USP2 3488/4885SMN1; SMN2 1839/4885DDB1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.